Association of CD103+ T cell infiltration with overall survival in solid tumors of the digestive duct and its potential in anti-PD-1 treatment: A review and meta-analysis

Wei Wei, Yun Ding, Jiajia He, Jun Wu

We looked into the most recent studies of digestive tumor patients and performed a meta-analysis to explore the association of CD103+ T cell infiltration with overall survival (OS) in solid tumors of the digestive duct. Major databases were searched. The hazard ratios (HR) and 95% confidence intervals (CI) for overall survival were extracted and pooled. A total of 1915 patients from 11 cohorts were included into the present meta-analysis. The pooled HR was 0.64 (95% CI: 0.42-0.96, \( P = 0.03 \)), suggesting that high CD103+ T cell infiltration is associated with better prognosis. Yet significant heterogeneity was revealed and located in the subgroup of CD4+CD103+ T cells. The pooled result indicated that CD103+ T cell infiltration in solid tumors of the digestive duct may possess predictive value for prognosis. Preclinical studies suggested that CD103+ T cell infiltration could predict response to anti-PD-1/PD-L1 treatment.

Key words: CD103+ T cell, digestive tumor, prognosis

INTRODUCTION

Tissue resident memory T (TRM) cells, defined by expression of CD69, CD103, CD49a and CD44, are recently recognized to play a vital role in anti-tumor immunity. CD103 is induced by tumor growth factor (TGF) \( \beta \) in the tumor microenvironment and uniquely expressed upon the surface of TRM cells to bind to the epithelial marker E-cadherin, which enables TRM cells to persist in epithelial tumor areas and therefore participate in local cytotoxic immune response. Accumulating studies suggest that TRM cells provide long-time protection in the peripheral tissue and respond fast to reexposure to tumor antigen. CD103+ T cells are enriched among tumor-specific T cells in close contact with tumor cells, where they express chemokine receptors to facilitate T cell homing and produce high levels of cytotoxic molecules to further strengthen target cancer cell killing. In the past decade or even earlier, several studies established that CD103+ T cell infiltration in various tumors confer improved prognosis, some even independently of the infiltration of CD8+ T cells, including non-small-cell lung cancer (NSCLC), cervical cancer, endometrial adenocarcinoma, ovarian cancer, breast cancer, renal cell carcinoma, urothelial cell carcinoma of the bladder and other tumors. However, researchers did not look into the infiltration of CD103+ T cell in digestive tumors until the past two or three years. In this systematic review and meta-analysis, we selected the latest published studies concerning CD103+ T cell infiltration in the tumors of the digestive duct and evaluated its prognostic significance.

RESULTS

Search results

As shown in Fig. 1, in the beginning, 266 studies from all databases surfaced by our searching strategy and 3 studies were found by manual search. We removed 18 duplicated studies, leaving 251 candidate studies. After preliminary screening for titles and abstracts, 233 studies were taken out according to the exclusion criteria. The remaining 18 studies were thoroughly scanned and 10 studies were deemed ineligible for our meta-analysis due to insufficient data. Eventually, 8 studies containing 11 cohorts, a total number of 1915 patients, were included into this meta-analysis.
Study characteristics and quality assessment

The included studies are listed in Table 1, all of which, surprisingly, were newly published from 2019 to 2020. These patients were from China, Germany and Australia and were pathologically diagnosed of gastric cancer, esophageal cancer, colorectal cancer, esophagogastric junction cancer, oral cancer or oropharyngeal cancer. Sample sizes ranged from 44 to 448. Specimens were obtained before any kind of treatment. All of the researchers measured CD103+ T cells via immunohistochemistry and fluorescence immunoassay if additional markers were detected. Some used whole slides and others tissue microarrays. Different cut-off standards from each study were listed in Table 1. Cut-off values varied from 6 cells/HPF in TMA to 37.58 cells/field in WS. Some researchers investigated all CD103+ T cells, while others focused on CD8+CD103+ T cells or CD4+CD103+ T cells. Some articles provided HRs with 95% CI, while the rest did not, where we extracted survival data from Kaplan-Meier (KM) curves using the method previously described. HRs with 95%CI and P values of each cohort were listed in Table 1.

Quality assessment was done by Review Manager 5.3, and risk of bias was shown in Fig. 2.

CD103+ T cell infiltration is associated with better prognosis

The HRs for OS extracted from each study were pooled in Fig. 3. Patients were divided into CD103+ T cell high infiltration and low infiltration groups. The pooled HR was 0.64 (95% CI: 0.42-0.96, \( P = 0.03 \)). Apparently, the result suggested that high CD103+ T cell infiltration is associated with longer overall survival and better outcome in solid tumors of the digestive duct. However, in this meta-analysis the \( I^2 = 81.4\% \) (\( P < 0.001 \)), meaning there is rather high heterogeneity among the included studies.

Heterogeneity from CD4+CD103+ T cell subgroup

Since significant heterogeneity occurred, we performed subgroup analysis to explore the potential cause. We divided these groups by areas, tumor types, and the measured T cell types (CD8+CD103+ T cell, CD4+CD103+ T cell or CD103+ T cell, Fig. 4). Subgroup analysis suggested that areas and tumor types were not the significant causes of heterogeneity. Namely, the association of CD103+ T cell infiltration with OS was generally reliable among patients from different areas as well as patients with different types of solid tumors in the digestive duct. However, as depicted in Fig. 4, the subgroup analysis concerning different CD103+T cell types showed that CD8+CD103+ T cell infiltration and total CD103+ T cell infiltration are both consistently associated with better prognosis (HR=0.58, 95% CI: 0.44-0.75, \( P < 0.001 \); HR=0.42, 95% CI: 0.25-0.70, \( P = 0.001 \)), while CD4+CD103+ T cell infiltration is associated with poor prognosis (HR=1.80, 95% CI: 1.34-2.42, \( P < 0.001 \)).
CD4+CD103+ T cell infiltration is associated with worse prognosis

In order to confirm the contracted prognostic influence of CD4+CD103+ T cell infiltration and further explain the heterogeneity in our meta-analysis, a sensitivity analysis was done. We ran an influence analysis in STATA 14.0 to evaluate the influence of each cohort on the pooled result. The chart exhibited that the two cohorts from the study focusing on the prognostic value of CD4+CD103+ T cell infiltration in gastric cancer patients generated the most remotely deviated results, while the results from the remaining 9 cohorts were consistent with the pooled result.

We also drew a Galbraith Radial plot to confirm the cause of heterogeneity. Evidently, the same two cohorts identified in the influence analysis stood out in the Galbraith Radial plot. These plots demonstrated that, in contrast to CD8+CD103+ T cell, CD4+CD103+ T cell infiltration may imply poor prognosis in tumors of the digestive duct.
Fig. 3. Forest plot of all the included studies.

Fig. 4. Subgroup analysis by cell types.
Publication bias

In order to discover potential publication bias, we drew a funnel plot and conducted Egger’s and Begg’s test via STATA 14.0. The generated P value was 0.125, meaning there was no significant publication bias among the included studies. There was no need for further trim and fill analysis.

DISCUSSION

Over the last decade, the function of CD103+ T cells in anti-tumor immunity has been researched in NSCLC, ovarian cancer, breast cancer, endometrial adenocarcinoma and other tumors. However, little attention was drawn to its role in digestive tumors until the past three years. To our knowledge, this is the first systematic review and meta-analysis to focus on the prognostic value of CD103+ T cells in solid tumors of the digestive duct. In this meta-analysis, 11 cohorts from 8 recently published studies were deemed eligible according to our inclusion and exclusion criteria. A total of 1915 patients from China, Germany and Australia suffering from gastrectic cancer, esophageal cancer, esophagogastric junction cancer, colorectal cancer, oral cancer and oropharyngeal cancer were included into this study. We extracted HRs with 95% CI from the original studies and reached the result that dense CD103+ T cell infiltration is associated with favorable clinical outcome in patients with digestive tumors (HR: 0.64, 95% CI: 0.42-0.96, P=0.03). Significant heterogeneity was found and subgroup analysis revealed that the prognostic value of CD4+CD103+ T cells was inconsistent with either CD8+CD103+ T cells or CD103+ T cells, which was further confirmed by sensitivity analysis. Egger’s and Begg’s test discovered no significant publication bias. It is worth pointing out that all the included studies were extremely up-to-date and published no later than 2019, because the function of CD103+ T cell in cancer immunity did not draw serious attention until the past three years. We believe our work is innovative and holds clinical significance.

During literature search, we also noticed some studies focusing on CD103+ T cell infiltration in digestive tumors, yet lacking sufficient data to be included into our meta-analysis. In line with the pooled results, a recent study investigated fresh surgical samples of human esophageal cancer and reported that CD8+CD103+ tumor infiltrating lymphocyte (TIL) infiltration is associated with better prognosis. This specific subgroup of TILs display potent proliferation and cytotoxic cytokine secretion ability, and elicit robust anti-tumor immunity after PD-1 blockade treatment regardless of chemotherapy. Another team from Germany looked into CD103+ T cells in resected pancreatic duct adenocarcinoma and proposed that high ratio of intraepithelial to total CD103+ T cells, instead of the actual numbers of CD103+ T cells or CD103+ intraepithelial lymphocytes, indicates improved overall survival in pancreatic cancer patients. Their work emphasized the distribution of CD103+ T cells rather than the number. As immunotherapy in intrahepatic cholangiocarcinoma (ICC) patients yields fruitful clinical benefits, a group of researchers tended extra attention to T RM cells in surgical samples of 33 ICC patients and observed higher infiltration of CD103+CD8+ TILs in intratumoral areas than in stroma. They noticed that, when compared to CD103+ T cells, CD103+ T cells exhibited stronger tumor specificity, proliferation and activation. These findings imply that the anti-tumor potential of CD103+ T cells is particularly contributed to the intratumoral subgroup rather than total 103+ T cells. Interestingly, all the studies included in the current meta-analysis investigated the numbers of intratumoral CD103+ T cells except one on human oral cancer, which stated that stromal, instead of intratumoral CD8+CD103+ TILs were correlated with a favorable prognosis.

Up until now, the mechanism underlying the role of CD103+ T cell in anti-tumor immunity still remain largely unknown. Through accumulating evidence from studies around the globe, a gradually cleared theory is being formed and consented among scientists investigating CD103+ T cells. It has been established that T RM cells, distinctively expressing CD103, respond much faster to reexposure of cognate antigens than circulating memory cells. Upon activation, T RM cells take up local immune surveillance and trigger recruitment of various immune cells by secretion of cytokines. The cytotoxic functions of CD8+CD103+ TILs are hinted through observed expression of granzyme A, granzyme B, perforin, and TIA-1, a marker for potential cytotoxicity. Functional studies proved that CD8+CD103+ TILs are capable of producing interferon (IFN) γ and tumor necrosis factor (TNF) α in tumor microenvironment, which is enhanced upon binding of CD103 to tumor cell E-cadherin. When compared to CD103+CD8+ T cells, intratumoral CD103+CD8+ T cells presented higher cytotoxicity.

The first decade of the 21st century witnessed the ground shaking revolution of immunotherapy in the battle against human cancers, as PD-1 blockade treatment reshaped the entire oncology field and benefited numerous lives. Naturally, the discussion over CD103+ T cell in anti-tumor immunity is brought under the background of cancer immunotherapy. We found quite a lot of studies implying a better response to PD-1 blockade in patients with dense CD103+ T cell infiltration. A previous study discovered increased infiltration of CD103+ T cells in colorectal cancers with microsatellite instability (MSI) in comparison to microsatellite stable (MSS) ones. Researchers found nearly thirty folds greater numbers of CD103+ T cells in tumor areas than in healthy epithelium from the same patient. The works of this team provides new enlightments for patients with colorectal cancer today, as MSI-high cancers are known to respond well to immunotherapy. The highlights of the study on intrahepatic cholangiocarcinoma mentioned above showed that ICCs with high proportions of CD69+CD103+ T cells presented higher CD8+ TIL infiltration, higher tumoral PD-L1 expression, and stronger T cell inflamed gene signature. Whereas ICCs with low proportions of CD69+CD103+ T cells exhibited enrichment of genes related to the Wnt/β-catenin and TGF-β pathways, notoriously acknowledged
to be responsible for immune treatment tolerance\textsuperscript{34}. In cytotoxicity experiments, after PD-1 neutralization, freshly isolated CD103\textsuperscript{+} TILs successfully killed autologous tumor cells and this cytotoxic activity was inhibited by CD103 blockade\textsuperscript{6,9}. CD103\textsuperscript{+}CD8\textsuperscript{+} TILs expressed dominant PD-1 and T-bet, rendering them to be better armed for immunotherapy. Consistently, researchers found that compared to CD103\textsuperscript{+}CD8\textsuperscript{+} TILs, PD-1 antibody induced stronger IFN\textgamma{} secretion in CD103\textsuperscript{+}CD8\textsuperscript{+} TILs (ref.\textsuperscript{24}). Similar results were observed in another study focusing on human gastric cancer, suggesting that CD103\textsuperscript{+}CD8\textsuperscript{+} T cells are primely responsive to PD-1 blockade and possess the potential to predict immunotherapy efficacy\textsuperscript{29}. In spite of expressing cell exhaustion markers, the cytotoxic potency of CD103\textsuperscript{+}CD8\textsuperscript{+} TILs could be restored after PD-1 blockade administration and CD103\textsuperscript{+} T cell expansion was observed during anti PD-1 treatment\textsuperscript{20,22}. Similar expansion of CD103\textsuperscript{+} T cells after PD-1 blockage were found in a xenograft mouse model of renal cancer, and the favorable treatment efficacy was reversed with depletion of CD103\textsuperscript{+} T cells, suggesting an indispensable character of CD103\textsuperscript{+} T cells in immunotherapy and its potential to optimize treatment efficacy\textsuperscript{19}. These findings sparkled novel ideas of future techniques to better expand

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig5.png}
\caption{Influence analysis mentioned in the text.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig6.png}
\caption{Galbraith Radial plot mentioned in the text.}
\end{figure}
CD103+ T cells like local immunization by mucosal vaccine21.40. Given the fact that CD103+ T cells are vigorous participants in tumor immunity, we recommend that early detection via immunohistochemistry upon surgical resection be conducted.

Several limitations are obvious in our study. To begin with, we intended to evaluate the association of CD103+ T cell infiltration with overall survival in tumors of the digestive duct, but only 11 cohorts from 8 studies fit our criteria. It is understandable as we mentioned that the issue of CD103+ T cell in tumors of the digestive duct did not draw focus until the past three years. The total number of patients was 1915, still not enough for a statistically solid meta-analysis. The tumor types covered gastric cancer, esophageal cancer, esophagogastric junction cancer, colorectal cancer, oral cancer and oropharyngeal cancer, which means our study lacks data of patients suffering from other digestive tumors, such as pancreatic cancer, liver cancer and gallbladder cancer. The patients in our meta-analysis were mainly from China, and only 501 out of 1915 were from Germany and Australia. Although subgroup analysis revealed no significant heterogeneity among patients from different areas, we still worry about potential geographic and racial bias. Our conclusion is yet to be further strengthened in more trials concerning other digestive tumors with patients from around the globe. In addition, all the included studies used different cut-off values to divide patients into high and low CD103+ T cell infiltration groups, sometimes even within the same tumor type, making it difficult to compare the result of one study to another. We believe that different tumors exhibit their own basic CD103+ T cell infiltration levels. For studies focusing on the same type of tumor, the researchers used different specimen forms of either whole tissue slides or tissue microarrays. They also adopted different methods to observe and calculate cell numbers. Therefore, it is fairly reasonable for researchers to come up with a unique cut-off value in each study.

We could not ignore the high heterogeneity we found in our meta-analysis, which lied among different subgroups of CD103+ T cells. No significant heterogeneity was found among the HRs of CD8+CD103+ T cell and CD103+ T cell infiltration. But apparently, the prognostic value of CD4+CD103+ T cells was quite the opposite of the pooled result. It is worth noticing that the researchers of this particular study discussing CD4+CD103+ T cells in gastric cancer were from the same team that almost simultaneously published another essay discussing CD8+CD103+ T cells in gastric cancer26. Providing the fact that these two highly qualified studies both came from the same lab, we do believe that the inconsistent prognostic values of CD8+CD103+ T cells and CD4+CD103+ T cells in gastric cancer is substantial. This team proved that the cytotoxic potency of CD8+ T cells are inhibited in patients with high CD4+CD103+ T cell infiltration, displaying impaired ability to produce granzyme B, IFNγ, TNFα and perforin. Such contradiction calls for more research into this specific subgroup of CD103+ T cells, not only in gastric cancer, but also in other tumors. Nonetheless, with all the studies currently accessible, we consider our conclusion that dense CD103+ T cell infiltration predicts better clinical outcome stands reliable.

CONCLUSIONS

In conclusion, the current meta-analysis indicates that CD103+ T cell infiltration is associated with favorable prognosis in solid tumors of the digestive duct, but the prognostic value of the CD4+CD103+ T cell subgroup calls for further research. Therefore we recommend CD103+ T cell infiltration evaluation by immunohistochemistry before anti-tumor treatment as a potential prognostic marker for patient survival. Preliminary function experiments and mouse models suggest that CD103+ T cells could also predict anti-PD-1/PD-L1 treatment response and are promising candidates to be targeted in cancer immunotherapy for enhanced efficacy.

Search strategy and selection criteria

Several major medicine related databases were searched, including PubMed, EMBASE, Cochrane Library, Web of Science, Wan fang Database, and China National Knowledge Infrastructure (CNKI) network until February 28, 2021. To identify studies referring to the prognostic significance of CD103+ T cells in tumors of the digestive duct, we adopted a comprehensive search strategy, combining text word and MeSH with the key words “prognosis” or “prognostic” and “CD103” and “cancer” or “tumor” or “neoplasm” or “carcinoma” or “malignancy” and “digestive” or “oral” or “pharyngeal” or “esophageal” or “gastric” or “pancreatic” or “liver” or “gallbladder” or “colon” or “rectal”. We also performed a manual search while screening the references of eligible studies in case any study was missed out. When the original article did not provide sufficient data for our analysis, we tried to contact the authors for details. The entire searching process was done under the guidance of PRISMA 2009 statement.

Ethical approval was not required for this meta-analysis because all the studies included in this meta-analysis were previously published high qualified studies, and the ethical approval of each study can be found in the original article respectively. All of the included studies were conducted according to the Declaration of Helsinki.

Inclusion and exclusion criteria

Inclusion criteria were as follows: only human studies were included; the patients were pathologically diagnosed of a certain solid tumor of the digestive duct; overall survival was observed; CD103+ T cell infiltration was evaluated; sufficient data were displayed such as HR or Kaplan-Meier curves. If duplicate studies occurred, only the most recent one was included.

Exclusion criteria were as follows: random cohorts pulled from public databases like the Cancer Genome Atlas (TCGA) or Surveillance, Epidemiology, and End Results (SEER) were excluded due to lack of detailed information. Studies focused on hematological malignancies of the digestive duct were excluded, such as lymphoma
or melanoma. In addition, reviews, letters, case reports, conference abstracts, nonhuman experimental studies and studies without sufficient exactable data were excluded.

After initial search, duplicate studies would be removed. Abstracts and titles would be screened and whole paper would be scanned to select the eventually studies to be included into this meta-analysis.

Quality assessment and data extraction

We assessed the quality of each included study according to Cochrane Handbook for Systematic Reviews of Interventions, using Review Manager 5.3 (the Cochrane Collaboration, Copenhagen, Denmark). Risk of bias was evaluated by two different reviews independently. Should disagreement occurred, a third reviewer would join to reach consensus.

Data extraction was also done by two reviews independently, collecting the surname of the first author, year of publication, patient area, type of tumor, sample size, specimen type of whole slide (WS) or tissue microarray (TMA), cut-off value, HR with 95% CI and P value. The extracted data were double checked by both reviews. Should disagreement occurred, a third reviewer would join to reach consensus.

Statistical analysis

The extracted data were processed using STATA 14.0 software (IBM Corp., Armonk, NY, USA). The HRs with 95% CI for OS were pooled. If a certain study did not provide HR and 95% CI directly, survival data were then extracted from the Kaplan-Meier curves, according to the established statistical methods from Tierney et al. Random effects model was applied unless there was no significant heterogeneity, in which case fixed effects model would be applied. If heterogeneity among the included studies occurred, further subgroup analysis would be done to find the factors that had significant influence on the pooled result. Heterogeneity was evaluated by Galbraith Radial plot. Sensitivity analysis was also done to explore the influence of each cohort on the pooled HR. Publication bias was evaluated Egger’s and Begg’s test. A funnel plot was drawn. If significant publication bias was found, trim and fill analysis would be performed to determine whether the pooled result was stable.

Acknowledgments: This work was supported by Basic Research Project of Changzhou Science and Technology Bureau (CJ20200113 to W.W.), and the Young Talent Development Plan of Changzhou Health Commission Bureau (CJ2020011 to W.W.), and the Young Talent Research Project of Changzhou Science and Technology Department (CJ2020011 to W.W.).

Author contribution: All authors contributed equally.

Conflicts of interest: The authors have no conflict of interest.

REFERENCES

1. Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C, Tihi I, Tartour E. Resident memory T cells, critical components in tumor immunology. J Immunother Cancer 2016;6(1):87. doi: 10.1186/s40425-018-0399-6

2. Topham DJ, Reilly EC. Tissue-Resident Memory CD8+ T Cells: From Phenotype to Function. Front Immunol 2018;9:515. doi: 10.3389/fimmu.2018.00515

3. Abd Hamid M, Colin-York H, Khalid-Alham N, Browne M, Cerundolo V, Chen JL, Yao X, Rosendo-Machado S, Waugh C, Maldonado-Perez D, Bowes E, Verrill C, Cerundolo V, Conlon CP, Fritzse M, Peng Y, Dong T. Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses. Cancer Immunol Res 2020;8(2):203-16. doi: 10.1158/2326-6066.cir-19-0554

4. Ling KL, Dalphy N, Bahl P, Saloo M, Maskell K, Pris J, Warren BF, George BD, Mortensen NJ, Cerundolo V. Modulation of CD103 expression on human colon carcinoma-specific CTL. J Immunol 2007;178(5):2908-15. doi: 10.4049/jimmunol.178.5.2908

5. Molodtsov A, Turk MJ. Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity. Front Immunol 2018;9:2810. doi: 10.3389/fimmu.2018.02810

6. Corgnac S, Boutet M, Kfouri M, Nallet C, Mami-Chouaib F, The Emerging Role of CD8+ Tissue Resident Memory T (TRM) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin. Front Immunol 2018;9:1904. doi: 10.3389/fimmu.2018.01904

7. O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang W-T, Rao AS, et al. Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer. Cancer Immunol Res 2019;7(6):896-909. doi: 10.1158/2326-6066.cir-18-0713

8. Bösmüller HC, Wagner P, Peper JK, Schuster H, Greif K, Beschorner C, Rammsense HG, Stevanovic S, Fend F, Staebler A. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer. Int J Gynecol Cancer 2016;26(4):671-9. doi: 10.1097/IGC.0000000000000672

9. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpréville V, Validire P, Besse B, Mami-Chouaib F. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 2015;194(7):3475-86. doi: 10.4049/jimmunol.1402711

10. Egelston CA, Avalos C, Tu TF, Rosario A, Wang R, Solomon S, Srinivasan G, Nelson MS, Huang Y, Lim MH, Simons DL, He TF, Yim JH, Kruper L, Mortimer J, Yost S, Guo W, Ruel C, Frankel PH, Yuan Y. Lee PP. Resident memory CD8 T cells within cancer islands mediate survival in breast cancer patients. JCI Insight 2019;4(19):e130000. doi: 10.1172/jci.insight.130000

11. Komdeur FL, Prins TM, van de Wall S, Plat A, Wisman GBA, Hollema H, Daemen T, Church DN, de Bruyn M, Nijman HW. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncotarget 2017;8(9):1338230. doi: 10.18632/oncotarget.1338230

12. Mann JE, Smith JD, Birkeland AG, Bellie E, Swiecicki P, Mierzwka M, Chinn SB, Shuman AG, Malloy KM, Casper KA, McLean SA, Monsanto JD, Prince MF, Carey TE, McGlynn JB, Specter ME, Brenner JC. Analysis of tumor-infiltrating CD103 resident memory T cell content in recurrent laryngeal squamous cell carcinoma. Cancer Immunol Immunother 2018;67(2):213-20. doi: 10.1007/s00262-018-2256-3

13. Park MH, Kwon SY, Choi JE, Gong G, Bae YK. Intratumoral CD103+ positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer. Histopathology 2020;77(4):560-9. doi: 10.1111/his.14126

14. Santoemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ Jr. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 2016;143(1):120-27. doi: 10.1016/j.ygyno.2016.07.105

15. Wang B, Wu S, Zeng H, Liu Z, Dong W, He H, Chen X, Dong X, Zheng L, Lin T, Huang J. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder. J Urol 2015;194(2):556-62. doi: 10.1016/j.juro.2015.02.2941

16. Wang ZQ, Miline K, Derocher H, Webb JR, Nelson BH, Watson PH, CD103 and Intratumoral Immune Response in Breast Cancer. Clin Cancer Res 2016;22(24):6290-97. doi: 10.1158/1078-0432.ccr-16-2840

17. Webb JR, Miline K, Nelson BH. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. Cancer Immunol Res 2015;3(8):926-35. doi: 10.1158/2326-6066.cir-14-0239
18. Workel HH, Komdeur FL, Wouters MC, Plat A, Klip HG, Eggink FA, Wisman GB, Arts HJ, Oonk MH, Mourits MJ, Yigit R, Versluijs M, Duiker EW, Hollema H, de Bruyn M, Nijman HW. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur J Cancer 2016;60:1-11. doi: 10.1016/j.ejca.2016.02.026

19. Zhou J, Liu L, Yang T, Lu B. Prognostic and therapeutic value of CD103(+) cells in renal cell carcinoma. Exp Ther Med 2018;15(6):4979-86. doi: 10.3892/etm.2018.6025

20. Han L, Gao QL, Zhou XM, Shi C, Chen GY, Song YP, Yao YJ, Zhao YM, Wen XY, Liu SL, Qi YM, Gao YF. Characterization of CD103+ CD6+ tissue-resident T cells in esophageal squamous carcinoma cell lines: may be tumor reactive and regenerated by anti-PD-1 blockade. Cancer Immunol Immunother 2020;69(8):1493-504. doi: 10.1007/s00262-020-02562-3

21. Blanc C, Hans S, Tran T, Granier C, Saldman A, Anson M, et al. Targeting Resident Memory T Cells for Cancer Immunotherapy. Frontiers in immunology. 2018;9. doi: 10.3389/fimmu.2018.01722.

22. Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson JK, W, Saw RPM, Thompson JF, Menzies AM, Long GV, Scolyer RA, Palendira U. CD103+ Tumor-Resident CD8+ T Cells Are Associated With Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. Clin Cancer Res 2018;24(13):3636-45. doi: 10.1158/1078-0432.ccr-17-2257

23. Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalim SC, Tackett AJ. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res 2019;79(6):1113-23. doi: 10.1158/0008-5472.can-18-1722

24. Wang P, Huang B, Gao Y, Yang J, Liang Z, Zhang N, Fu X, Li L. CD103+CD8+ T lymphocytes in non-small cell lung cancer are phenotypically and functionally primed to respond to PD-1 blockade. Cell Immunol 2018;325:48-55. doi: 10.1016/j.cellimm.2018.02.002

25. Chu Y, Liao J, Li J, Wang J, Xu X, Xu Z, Zheng L, Xu J, Li L. CD103+ tumor-infiltrating lymphocytes predict favorable prognosis in patients with esophageal squamous cell carcinoma. J Cancer 2019;10(1):5234-43. doi: 10.7150/jca.30354

26. Gu Y, Chen Y, Xin K, Cao Y, Liu X, Lv K, He X, Lin C, Liu H, Li H, He H, Qin J, Li R, Zhang H, Zhang W. Intrapolumal CD103+CD6+ T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients. Oncoimmunology 2020;9(1):184402. doi: 10.1080/21624020.2020.184402

27. Hu W, Sun R, Chen L, Zheng X, Jiang P. Prognostic significance of resident CD103+CD8+ T cells in human colorectal cancer tissues. Acta Histochemica 2019;121(5):657-63. doi: 10.1016/j.acthis.2019.05.009

28. Kneif J, Lazar-Karsten P, Hummel R, Wellner U, Thorns C. PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival. Pathol Res Pract 2019;215(6):152402. doi: 10.1016/j.prp.2019.03.030

29. Li R, Liu H, Cao Y, Wang J, Chen Y, Qi Y, Lv K, Liu X, Yu K, Lin C, Zhang H, He H, Li H, Chen L, Shen Z, Qin J, Zhang W, Sun Y, Xu J. Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoral CD103+CD8+ T cells conferring favourable prognosis. Br J Cancer 2020;122(10):1525-34. doi: 10.1038/s41416-020-0813-y

30. Solomon B, Young RJ, Bressel M, Cernel J, Savas P, Liu H, Urban D, Thai A, Cooper C, Fua T, Neeson P, Lui S, Porendu SV, Rischin D. Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. Ann Oncol 2019;30(10):1638-46. doi: 10.1093/annonc/mdz271

31. Xiao Y, Li H, Mao Y, Yang Q, Fu Q, Wu CC, Liu B, Sun ZJ. CD103+ T and Dendritic Cells Indicate a Favorable Prognosis in Oral Cancer. J Dent Res 2019;98(13):1480-87. doi: 10.1177/0022034519882618

32. Yan W, Huiming, L, Lujun, C, Bingfeng, L, Jingting, J. Infiltration and significance of tissue-resident CD8+ T cells in gastric cancer. Linchuang jianyan zazhi. 2019;37(4):251-6. (in Chinese).

33. Lohneis P, Sinn M, Bischoff S, Jühling A, Pelzer U, Wloclaka L, Brahma M, Sinn BV, Denkert C, Oettle H, Bläker H, Riess H, Jöhnkens K, Striplier JK. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 2017;83:290-301. doi: 10.1016/j.ejca.2017.06.016.

34. Kim HD, Jeong S, Park S, Lee YJ, Yu YS, Kim D, Song GW, Lee JH, Kim SY, Shin J, Shin EC, Hwang S, Yoo C, Park SH. Implication of CD69+CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma. Liver Int 2021;41(4):764-76. doi: 10.1111/liv.14814

35. Schenkel JM, Fraser KA, Beura LK, Paeken KE, Veveys V, Masopust D. T cell memory. Resident memory CD8+ T cells trigger protective innate and adaptive immune responses. Science 2014;346(6205):98-101. doi: 10.1126/science.1254536

36. Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 2014;20(2):434-44. doi: 10.1158/1078-0432.ccr-13-1877

37. Hombrink P, Helbig C, Backer RA, Piet B, Oja AE, Stark R, Brasser G, Jongejan A, Jonkers RE, Nota B, Clevers HC, Moerland PD, Amsen D, van Lier RA. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. Nat Immunol 2016;17(12):1467-78. doi: 10.1038/ni.3589

38. Ganesan AP, Clarke J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton SY, D, Thai A, Cooper C, Fua T, Neeson P, Loi S, Porceddu SV, Rischin D. Characterization of CD103(+) cells in renal cell carcinoma. Exp Ther Med 2018;15(6):4979-86. doi: 10.3892/etm.2018.6025

39. Quinn E, Hawkins N, Yip YL, Suter C, Ward R, Brassier G, Jongejan AJ, Jonkers RE, Nota B, Basak O, Clevers HC, Moerland PD, Amsen D, van Lier RA. Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells. Nat Immunol 2016;17(12):1467-78. doi: 10.1038/ni.3589

40. Dumauthioz N, Labiano S, Romero P. Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy. Front Immunol 2017;8:2076. doi: 10.3389/fimmu.2018.02076

41. Tierney JF, Stewart LA, Gheris D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. doi: 10.1186/1745-6215-8-16